Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inactivated Bivalent Enterovirus Vaccine Phase I/II Clinical Trial
NCT06063057Phase 2Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bivalent enterovirus vaccine (CA16/EV71), inactivated in HIV-associated central nervous system involvement (HAND) and herpangina (4 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Safety based on adverse events at 30 days and Immunogenicity of the trial vaccine at 30 days. Started Sep 2023; status: completed.
02
Drugs
bivalent enterovirus vaccine (CA16/EV71), inactivated
03
Conditions
HIV-associated central nervous system involvement (HAND)herpangina
Beyond the preview
Go deeper on NCT06063057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06063057.